MRK
30
-8
HCP
43
-2
MTB
46
-2
DHR
39
-6
WY
50
-7
MS
58
-3
MAC
67
-7
PRGO
32
-3
NOV
40
-2
MCK
55
-4
LUV
45
-3
KLAC
54
-3
MAS
56
-6
SJM
24
-7
BRK.B
31
-2
LB
12
11
APH
61
-6
VFC
53
-6
UNM
70
-2
AMAT
40
-3
MRK
30
-8
HCP
43
-2
MTB
46
-2
DHR
39
-6
WY
50
-7
MS
58
-3
MAC
67
-7
PRGO
32
-3
NOV
40
-2
MCK
55
-4
LUV
45
-3
KLAC
54
-3
MAS
56
-6
SJM
24
-7
BRK.B
31
-2
LB
12
11
APH
61
-6
VFC
53
-6
UNM
70
-2
AMAT
40
-3
Financhill
Back

Oryzon Genomics SA 10K Form

Sell
17

ORYZF
Oryzon Genomics SA

Last Price:
1.62
Seasonality Move:
-0.37%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ORYZF News And Ratings

See the #1 stock for the next 7 days that we like better than ORYZF

ORYZF Financial Statistics

Sales & Book Value

Annual Sales: $18.99K
Cash Flow: $0
Price / Cash Flow: 0
Annual Sales: $1.72
Price / Book: 0.95

Profitability

EPS (TTM): -0.06900
Net Income (TTM): $-4.4M
Gross Margin: $15.1M
Return on Equity: 0%
Return on Assets: 0%

Oryzon Genomics SA Earnings Forecast

Key Oryzon Genomics SA Financial Ratios

  • The Selling, General & Administrative Expenses for ORYZF have been equal to 29,752.50% of Gross Profit Margin.
  • The Research & Development expenses have been 491.88% of Revenue.
  • The Interest Expense is -56.47% of Operating Income.
  • Per Share Earnings over the last 10 years have been positive in 5 years.

Oryzon Genomics SA Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: OTCM
Industry: Biotechnology
Sector: Health Care
Current Symbol: ORYZF
Website: oryzon.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ORYZF Technical Analysis vs Fundamental Analysis

Sell
17
Oryzon Genomics SA (ORYZF) is a Sell

Is Oryzon Genomics SA a Buy or a Sell?